SCHEMBL14788168

SCHEMBL14788168

COc1ccc(-c2noc(CBr)n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 1/20 0.74
▸ L3MBTL1 Q9Y468 5/20 0.66
▸ TDP1 Q9NUW8 3/20 0.66
▸ KMT2A Q03164 3/20 0.66
▸ HTT P42858 2/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ MAPT P10636 7/20 0.63
▸ NPC1 O15118 4/20 0.63
▸ RAB9A P51151 4/20 0.63
▸ TSHR P16473 5/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ LMNA P02545 3/20 0.62
▸ KDM4E B2RXH2 2/20 0.62
▸ ATM Q13315 1/20 0.62
▸ ALOX15 P16050 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ CASP3 P42574 1/20 0.60
▸ SENP8 Q96LD8 1/20 0.60
▸ SENP7 Q9BQF6 1/20 0.60
▸ SENP6 Q9GZR1 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17513948 0.84 SIRT2 (0.65) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL1220782 0.84 SMN1; SMN2 (0.66) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL8900040 0.84 LMNA (0.66) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL7952282 0.83 SIRT2 (0.72) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL28869603 0.82 MAPT (0.61) TDP1KMT2AMEN1MAPTNPC1
SCHEMBL10173253 0.81 SMN1; SMN2 (0.59) L3MBTL1TDP1HTTMAPTNPC1
SCHEMBL15133520 0.81 KMT2A (0.63) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL7148635 0.81 SIRT2 (0.70) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL27035148 0.81 ALDH1A1 (0.65) SIRT2L3MBTL1TDP1KMT2AHTT
SCHEMBL203702 0.80 S1PR1 (0.55) SIRT2L3MBTL1TDP1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 — — CN claimed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 — — CN claimed
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 — — CN disclosed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 — — CN disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 — — US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SIRT2 2237/4885L3MBTL1 703/4885TDP1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback